John Zhang
Chief Tech/Sci/R&D Officer at IMMUNE PHARMACEUTICALS, INC.
Profile
John Zhang is currently the Vice President of Research & Development at Immune Pharmaceuticals, Inc. He previously worked as the Director of Preclinical Pharmacology & Toxicology at Pharmacopeia LLC, Head of Toxicology at Enzon Pharmaceuticals, Inc., and Vice President of Preclinical Research & Development at EnzymeRx LLC.
He holds a graduate degree from the University of California, Los Angeles and a doctorate degree from Guangzhou University.
John Zhang active positions
Companies | Position | Start |
---|---|---|
IMMUNE PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2017-12-10 |
Former positions of John Zhang
Companies | Position | End |
---|---|---|
Pharmacopeia LLC
Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Corporate Officer/Principal | - |
ENZON PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
EnzymeRx LLC
EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Chief Tech/Sci/R&D Officer | - |
Training of John Zhang
University of California, Los Angeles | Graduate Degree |
Guangzhou University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
ENZON PHARMACEUTICALS, INC. | Health Technology |
Private companies | 3 |
---|---|
Pharmacopeia LLC
Pharmacopeia LLC Pharmaceuticals: MajorHealth Technology Pharmacopeia LLC develops small molecule therapeutics to address significant medical needs. The firm operates as clinical development stage Biopharmaceutical Company which focuses on discovering and developing novel small molecule therapeutics to address medical needs. The company was founded by John J. Baldwin in February 2002 and is headquartered in Cranbury, NJ. | Health Technology |
EnzymeRx LLC
EnzymeRx LLC BiotechnologyHealth Technology EnzymeRx LLC develops pegylated uricase for the treatment of resistant and refractory related indications. The company was founded by Anthony S Fiorino in 2008 and is headquartered in Paramus, NJ. | Health Technology |
Immune Pharmaceuticals, Inc.
Immune Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Immune Pharmaceuticals, Inc. is a biopharmaceutical company developing novel therapeutic agents for the treatment of immunologic and inflammatory diseases. Its lead product, Bertilimumab, is a human monoclonal antibody that binds eotaxin-1, a chemokine that attracts eosinophils to the site of inflammation. Bertilimumab has shown promising clinical activity in bullous pemphigoid and has been studied in other conditions including allergic rhinitis and ulcerative colitis, and may have application in other diseases, including atopic dermatitis, asthma, and other diseases. It is also developing NanoCyclo, a topical nano-encapsulated formulation of cyclosporine, for the treatment of atopic dermatitis (AD) and psoriasis. The company was founded by Daniel Gedeon Teper on March 9, 1993 and is headquartered in Englewood Cliffs, NJ. | Health Technology |
- Stock Market
- Insiders
- John Zhang